Nektar Therapeutics (NKTR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Nektar Therapeutics (NKTR) Healthcare & Pipeline Overview

Nektar Therapeutics is a biopharmaceutical company focusing on discovering and developing novel medicines, particularly in immuno-oncology and autoimmune diseases. With a pipeline of clinical-stage assets and strategic collaborations, Nektar aims to address unmet medical needs through innovative therapies and partnerships within the competitive biotechnology landscape.

What Is the Investment Thesis for NKTR?

Nektar Therapeutics presents a compelling investment thesis based on its innovative pipeline of clinical-stage immuno-oncology and autoimmune disease candidates. Key value drivers include the potential success of Bempegaldesleukin in ongoing Phase 3 trials for various cancer indications, with results expected to influence valuation significantly. The development of NKTR-358 for autoimmune diseases represents another growth catalyst, addressing a substantial market with limited treatment options. Strategic collaborations with major pharmaceutical companies provide financial resources and validation of Nektar's technology. However, risks include clinical trial failures, regulatory hurdles, and competition from established players in the biotechnology sector. The company's high gross margin of 80.1% suggests strong potential profitability if its key drug candidates achieve regulatory approval and commercial success. Investors should closely monitor clinical trial outcomes and partnership developments to assess the long-term value of Nektar Therapeutics.

Based on FMP financials and quantitative analysis

NKTR Key Highlights

Market Cap of $2.10B reflects investor sentiment regarding Nektar's pipeline and potential for future growth.

• Gross Margin of 80.1% indicates a strong ability to generate profit from its products and collaborations.
• Profit Margin of -284.2% highlights the significant investment in research and development typical of biotechnology companies in the clinical stage.
• Beta of 1.18 suggests that the stock is slightly more volatile than the overall market.
• No dividend is currently offered, which is common for growth-oriented biopharmaceutical companies reinvesting earnings into research and development.

Who Are NKTR's Competitors?

NKTR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NKTR's Key Strengths?

Innovative pipeline of clinical-stage drug candidates.

• Proprietary polymer technology enhances drug efficacy.
• Strategic collaborations with major pharmaceutical companies.
• Experienced management team with expertise in drug development.

What Are NKTR's Weaknesses?

High R&D spending and negative profit margins.

• Reliance on clinical trial success and regulatory approvals.
• Competition from established pharmaceutical companies.
• Limited commercialized products and revenue streams.

What Could Drive NKTR Stock Higher?

Clinical trial results for Bempegaldesleukin in metastatic melanoma (2026-2027).

• Clinical trial results for NKTR-358 in systemic lupus erythematosus (2026-2027).
• Advancement of NKTR-255 through Phase 1/2 clinical trials for hematological malignancies and solid tumors.
• Expansion of strategic collaborations with pharmaceutical companies to co-develop and commercialize drug candidates.

What Are the Key Risks for NKTR?

Negative return on equity (-87.0%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for key drug candidates.
• Regulatory setbacks and delays in drug approvals.
• Competition from established pharmaceutical companies and biosimilars.
• High R&D spending and negative profit margins.
• Changes in healthcare regulations and reimbursement policies.

What Are the Growth Opportunities for NKTR?

• Expansion of Bempegaldesleukin into new cancer indications: Bempegaldesleukin, Nektar's lead drug candidate, has the potential to expand beyond its current clinical trials into additional cancer types.
• Development of NKTR-358 for autoimmune diseases: NKTR-358, a cytokine Treg stimulant, targets autoimmune diseases such as systemic lupus erythematosus and ulcerative colitis. The autoimmune disease therapeutics market is estimated to reach $63.8 billion by 2027, driven by increasing prevalence and demand for novel therapies. Successful clinical trials and regulatory approval could position NKTR-358 as a key player in this market within the next 5-7 years.
• Advancement of NKTR-255 for hematological malignancies and solid tumors: NKTR-255, an IL-15 receptor agonist, is being developed for hematological malignancies and solid tumors. The global oncology market is projected to reach $286.6 billion by 2030, offering a substantial opportunity for Nektar to address unmet needs in these areas. Clinical trial progress and strategic partnerships will be crucial for realizing this growth potential over the next 5-7 years.
• Strategic collaborations with pharmaceutical companies: Nektar's collaboration agreements with major pharmaceutical companies provide financial resources and validation of its technology platform. Expanding these partnerships and securing new collaborations can accelerate the development and commercialization of its drug candidates. The pharmaceutical industry is increasingly focused on external innovation, creating opportunities for Nektar to leverage its expertise and pipeline.
• Leveraging proprietary polymer technology: Nektar's proprietary polymer technology enhances the efficacy and safety of existing or novel drug candidates. This technology can be applied to a wide range of therapeutic areas, providing a competitive advantage and opportunities for developing new products. Continued innovation and application of this technology will be crucial for sustaining long-term growth and differentiation in the biotechnology market.

What Are NKTR's Competitive Advantages?

• Proprietary polymer technology enhances drug efficacy and safety.
• Strong intellectual property portfolio protects drug candidates.
• Strategic collaborations with major pharmaceutical companies provide financial resources and validation.
• Clinical-stage pipeline with multiple drug candidates addressing unmet medical needs.

What Does NKTR Do?

Nektar Therapeutics, founded in 1990 and headquartered in San Francisco, California, is a biopharmaceutical company dedicated to discovering and developing innovative medicines for areas of high unmet medical need. The company focuses primarily on immuno-oncology, autoimmune diseases, and other therapeutic areas where its proprietary polymer technology can enhance the efficacy and safety of existing or novel drug candidates. Nektar's lead product candidate, Bempegaldesleukin, is a CD122-preferential interleukin-2 (IL-2) pathway agonist that has been in various clinical trials, including Phase 3 studies for metastatic melanoma, renal cell carcinoma, and other cancers. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant for autoimmune diseases like systemic lupus erythematosus and ulcerative colitis, and NKTR-255, an IL-15 receptor agonist for hematological malignancies and solid tumors. Nektar has established numerous collaborations with major pharmaceutical companies, including Takeda, AstraZeneca, UCB Pharma, Roche, Bausch Health, Pfizer, Amgen, Bristol-Myers Squibb, and others, to advance its pipeline and leverage its technology platform. These partnerships are crucial for funding research and development efforts and expanding the potential applications of Nektar's drug candidates. Nektar continues to focus on advancing its clinical programs and exploring new opportunities to address significant medical challenges.

What Products and Services Does NKTR Offer?

• Discovers and develops innovative medicines.
• Focuses on areas of unmet medical need.
• Develops therapies for cancer and autoimmune diseases.
• Utilizes proprietary polymer technology to enhance drug efficacy.
• Conducts clinical trials to evaluate drug candidates.
• Collaborates with major pharmaceutical companies to advance its pipeline.

How Does NKTR Make Money?

• Develops and patents novel drug candidates.
• Conducts clinical trials to demonstrate safety and efficacy.
• Out-licenses or co-develops drug candidates with pharmaceutical partners.
• Generates revenue through collaboration agreements, milestone payments, and royalties.

What Industry Does NKTR Operate In?

Nektar Therapeutics operates within the competitive biotechnology industry, characterized by high R&D spending, stringent regulatory requirements, and intense competition. The immuno-oncology and autoimmune disease markets are experiencing significant growth, driven by increasing prevalence and unmet medical needs. Key trends include the development of novel immunotherapies, personalized medicine approaches, and combination therapies. Nektar's success depends on its ability to differentiate its drug candidates through enhanced efficacy, improved safety profiles, and strategic partnerships. Competition includes established pharmaceutical companies and other biotechnology firms developing similar therapies.

Who Are NKTR's Key Customers?

• Patients with cancer and autoimmune diseases.
• Pharmaceutical companies seeking innovative drug candidates.
• Healthcare providers prescribing Nektar's therapies.
• Research institutions collaborating on drug development.

Nektar Therapeutics (NKTR) Valuation Context

Valued at $2.10B, NKTR is classified as a mid-cap stock. Relative to its peer group, NKTR's quantitative score of 21/100 is below the peer average of 83/100.

NKTR Revenue & Earnings Trend

In Q2 2026, NKTR generated $10.1M in top-line revenue, marking a sequential decrease of 6.7%. The company recorded a net loss of $40.6M, with diluted EPS of $-1.23. Revenue has contracted over three consecutive quarters, which investors in this mid-cap Healthcare stock should monitor closely. Across the four most recent quarters, NKTR averaged $-1.68 in diluted EPS.

Company Profile

Nektar Therapeutics operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Francisco, US. The company is led by CEO Howard W. Robin. NKTR has traded publicly since 1994.

Return on equity for Nektar Therapeutics stands at -87.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -20.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -9.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.21 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.7%, the inverse of the P/E and a quick read on earnings relative to price.

Nektar Therapeutics's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.11 places it in the grey zone, a middle ground that warrants monitoring.

Nektar Therapeutics has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 10.4% above estimates on average.

Wall Street analysts project Nektar Therapeutics revenue of about $42.0M for fiscal 2026, with EPS near $-8.23. The estimate reflects 9 contributing analysts.

Over the past six months, Nektar Therapeutics insiders filed 10 SEC Form 4 transactions — 8 sales and 2 purchases. On net that is roughly 42K shares acquired (about $875K) — insiders putting money in tends to read as conviction.

NKTR Financials

NKTR Latest News

NKTR Analyst Consensus

NKTR MoonshotScore

What Investors Ask About Nektar Therapeutics (NKTR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources